乳腺癌患者高血压病风险因素相关性分析

发布时间：2018-05-28 09:14

本文选题：乳腺癌 + 高血压病　；参考：《大连医科大学》2017年硕士论文

【摘要】：背景:全球人口老龄化是目前的一种趋势,人类平均寿命的提高,高血压病和乳腺癌的发病率亦逐年增长,均成为全球范围内危害人类身体健康的常见疾病。高血压病发病机制复杂,目前尚未有统一的观点。乳腺癌是女性常见恶性肿瘤,严重危害女性身心健康,其发病机制亦未阐明。二者是否有发生发展的关联机制,是目前研究的热点。目的:探讨乳腺癌患者分子分型的免疫组化指标中ER、PR、Her-2、P53、Ki67%%与高血压病的相关性。方法:采集2013年1月~2016年12月大连市相关医院乳腺外科收治的原发性乳腺癌患者800例,其中合并高血压病患者为304例。所有乳腺癌患者均接受乳腺癌手术治疗或术前肿瘤穿刺,并行常规病理学检查,根据病理科医师报告的病理单记录患者的免疫组化结果,通过是否合并高血压病进行分组。并制成四格表,利用卡方检验进行分析,P0.05差异有统计学意义,采用卡方检验及Fisher确切概率法单因素分析乳腺癌免疫组化指标ER、PR、Her-2、P53、Ki67%与罹患高血压病的相关性;采取Logistic回归多因素分析评价乳腺癌患者不同免疫组化指标罹患高血压病的独立危险因素,全部统计检验的检验水准取P0.05,采用双侧检验。结果:乳腺癌患者中年龄以及病理学免疫组化指标中ER、PR与罹患高血压病存在相关性,p0.01,差异有统计学意义。乳腺癌患者病理学免疫组化指标中Her-2、P53、Ki67%与高血压的发生不存在相关性,p0.05,差异无统计学意义。多因素logistic回归分析乳腺癌患者中年龄以及病理学免疫组化指标中ER、PR,p0.05差异有统计学意义,其中乳腺癌患者PR和年龄段为35~50岁,是高血压病发生的独立危险因素。乳腺癌患者病理学免疫组化指标中ER以及年龄在小于35岁、大于50岁乳腺癌患者与高血压病的分析中,p0.05差异无统计学意义,乳腺癌患者病理学免疫组化指标中ER以及年龄在小于35岁、大于50岁乳腺癌患者为高血压病发生的非独立危险因素。统计软件选择SPSS17.0中文版。结论:1、乳腺癌患者中年龄以及病理学免疫组化指标中ER+、PR+与罹患高血压病相关。2、乳腺癌患者病理学免疫组化指标中PR和年龄段为35~50岁,是高血压病发生的独立危险因素。
[Abstract]:Background: the aging of the global population is a trend at present. With the increase of average life expectancy, the incidence of hypertension and breast cancer are increasing year by year. The pathogenesis of hypertension is complex, and there is no unified view at present. Breast cancer is a common malignant tumor in women, which seriously endangers women's physical and mental health. Whether the two have the mechanism of occurrence and development is the focus of current research. Objective: to investigate the correlation between ERP PRA Her- 2 P 53 Ki 67% and hypertension in molecular classification of breast cancer. Methods: from January 2013 to December 2016, 800 patients with primary breast cancer were collected from breast surgery department of Dalian related hospital, including 304 patients with hypertension. All breast cancer patients were treated with breast cancer surgery or preoperative tumor puncture, and the routine pathological examination was performed. According to the single pathological findings reported by pathologists, the patients were divided into groups according to whether they were complicated with hypertension or not. The results showed that there was statistical significance in using chi-square test to analyze the difference of P05. The correlation between breast cancer and hypertension was analyzed by using chi-square test and Fisher exact probability method. Logistic regression multivariate analysis was used to evaluate the independent risk factors of hypertension in breast cancer patients with different immunohistochemical indexes. The test level of all statistical tests was P0.05 and bilateral test was used. Results: there was a significant correlation between ERP and hypertension in patients with breast cancer (P 0.01). There was no correlation between the incidence of hypertension and the incidence of hypertension (P 0.05) in the pathological immunohistochemical index of breast cancer patients (P 0.05), and there was no significant difference between them. The multivariate logistic regression analysis showed that there were significant differences in age and pathological immunohistochemical markers in breast cancer patients. Among them, PR and age of breast cancer patients were 35 ~ 50 years old, which were independent risk factors of hypertension. There was no significant difference between breast cancer patients and hypertension patients in the analysis of ER and ER in breast cancer patients aged less than 35 years and hypertension in patients over 50 years old. The ER and ER in breast cancer patients aged less than 35 years and breast cancer patients over 50 years old were independent risk factors of hypertension. Chinese version of SPSS17.0 is selected for statistical software. Conclusion: age and ER PR in breast cancer patients and pathological immunohistochemical markers are associated with hypertension, and PR and age in breast cancer patients are 35 ~ 50 years old, which are independent risk factors of hypertension.
【学位授予单位】：大连医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9;R544.1

【相似文献】